Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH. The company was founded in 2008 and is headquartered in Livonia, Michigan.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GEMP
CUSIPN/A
Phone734-245-1700
Debt
Debt-to-Equity Ratio0.50
Current Ratio4.64
Quick Ratio4.64
Price-To-Earnings
Trailing P/E Ratio-0.68
Forward P/E Ratio-1.13
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.37 per share
Price / Book6.08
Profitability
EPS (Most Recent Fiscal Year)($3.23)
Net Income$-33,410,000.00
Net MarginsN/A
Return on Equity-235.82%
Return on Assets-107.74%
Miscellaneous
Employees18
Outstanding Shares14,270,000
Market Cap$30.96 million
Gemphire Therapeutics (NASDAQ:GEMP) Frequently Asked Questions
What is Gemphire Therapeutics' stock symbol?
Gemphire Therapeutics trades on the NASDAQ under the ticker symbol "GEMP."
How were Gemphire Therapeutics' earnings last quarter?
Gemphire Therapeutics Inc (NASDAQ:GEMP) released its quarterly earnings results on Monday, August, 13th. The company reported ($0.47) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.52) by $0.05. View Gemphire Therapeutics' Earnings History.
When is Gemphire Therapeutics' next earnings date?
What price target have analysts set for GEMP?
6 brokers have issued 1 year price objectives for Gemphire Therapeutics' stock. Their predictions range from $6.00 to $30.00. On average, they expect Gemphire Therapeutics' stock price to reach $20.50 in the next year. This suggests a possible upside of 811.1% from the stock's current price. View Analyst Price Targets for Gemphire Therapeutics.
What is the consensus analysts' recommendation for Gemphire Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gemphire Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gemphire Therapeutics.
What are Wall Street analysts saying about Gemphire Therapeutics stock?
Here are some recent quotes from research analysts about Gemphire Therapeutics stock:
- 1. According to Zacks Investment Research, "Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company's product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. " (8/15/2018)
- 2. Canaccord Genuity analysts commented, "We expect the study to continue under higher safety scrutiniy, and will carefully watch for any changes." (8/13/2018)
Who are some of Gemphire Therapeutics' key competitors?
Some companies that are related to Gemphire Therapeutics include TapImmune (TPIV), Intec Pharma (NTEC), Trevena (TRVN), Zynerba Pharmaceuticals (ZYNE), Iterum Therapeutics (ITRM), Infinity Pharmaceuticals (INFI), MOTIF BIO PLC/S (MTFB), Processa Pharmaceuticals (PCSA), VBI Vaccines (VBIV), Aptevo Therapeutics (APVO), Catalyst Biosciences (CBIO), CTI BioPharma (CTIC), Molecular Templates (MTEM), Oncomed Pharmaceuticals (OMED) and Aerpio Pharmaceuticals (ARPO).
Who are Gemphire Therapeutics' key executives?
Gemphire Therapeutics' management team includes the folowing people:
- Dr. Charles L. Bisgaier, Co-Founder, Chairman & Chief Scientific Officer (Age 64)
- Dr. Steven R. Gullans, CEO & Director (Age 65)
- Dr. Lee Golden M.D., Chief Medical Officer (Age 50)
- Mr. Jeffrey S. Mathiesen CPA, CFO & Sec. (Age 57)
- Mr. Seth Reno, Chief Commercial Officer (Age 51)
When did Gemphire Therapeutics IPO?
(GEMP) raised $30 million in an initial public offering on Friday, August 5th 2016. The company issued 3,000,000 shares at $10.00 per share. Jefferies and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.
Has Gemphire Therapeutics been receiving favorable news coverage?
Headlines about GEMP stock have been trending somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Gemphire Therapeutics earned a news impact score of 0.18 on Accern's scale. They also assigned media stories about the company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Gemphire Therapeutics.
Who are Gemphire Therapeutics' major shareholders?
Gemphire Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Northpointe Capital LLC (4.91%), Millennium Management LLC (1.37%), Stonepine Capital Management LLC (0.72%), Nomura Holdings Inc. (0.38%), Acadian Asset Management LLC (0.20%) and JBF Capital Inc. (0.14%). Company insiders that own Gemphire Therapeutics stock include Andy Sassine and Steven R PhD Gullans. View Institutional Ownership Trends for Gemphire Therapeutics.
Which institutional investors are selling Gemphire Therapeutics stock?
Which institutional investors are buying Gemphire Therapeutics stock?
GEMP stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Nomura Holdings Inc., Acadian Asset Management LLC and JBF Capital Inc.. Company insiders that have bought Gemphire Therapeutics stock in the last two years include Andy Sassine and Steven R PhD Gullans. View Insider Buying and Selling for Gemphire Therapeutics.
How do I buy shares of Gemphire Therapeutics?
Shares of GEMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Gemphire Therapeutics' stock price today?
One share of GEMP stock can currently be purchased for approximately $2.25.
How big of a company is Gemphire Therapeutics?
Gemphire Therapeutics has a market capitalization of $30.96 million. The company earns $-33,410,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis. Gemphire Therapeutics employs 18 workers across the globe.
How can I contact Gemphire Therapeutics?
Gemphire Therapeutics' mailing address is 17199 N. LAUREL PARK DRIVE SUITE 401, LIVONIA MI, 48152. The company can be reached via phone at 734-245-1700 or via email at [email protected]
MarketBeat Community Rating for Gemphire Therapeutics (NASDAQ GEMP)
MarketBeat's community ratings are surveys of what our community members think about Gemphire Therapeutics and other stocks. Vote "Outperform" if you believe GEMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
